Morning Brief — August 25, 2026

Market Overview

Equity futures are pointing modestly higher (+0.5% SPY pre-bell) as chip stocks attempt a recovery after Monday’s semiconductor-led selloff, with the market laser-focused on NVIDIA’s earnings Wednesday. The macro backdrop is complicated: a strong August flash PMI (Composite 56, Services 56.8) signals robust demand but complicates the Fed’s rate-cut path, while the 10-year yield has slipped to 4.71% and the dollar sits at 3-month lows on Treasury buyback plans — a tailwind for commodities and EM. Geopolitical noise around US-Iran sanctions is adding a risk-off undercurrent beneath what should be a bullish earnings week for AI infrastructure names.

Claude’s Call

UP — The dip in semis yesterday was positioning ahead of NVIDIA’s print, not a fundamental break, and MRVL’s blowout quarter (+6.2% reaction, $2.91 EPS) is the best leading indicator that AI infrastructure demand is intact. With MRVL confirming Alphabet custom chip wins and BofA flagging 8 chip names as enhanced buying opportunities, the setup for a pre-NVDA squeeze into Wednesday’s close is real — S&P grinds higher, led by tech.

Top Movers

ALVO (+18.51%) — $5.25 → $6.00 (+14.3% upside) Thesis: This is a legitimate catalyst-driven move, not a pump — BofA initiated with a Buy and $7 PT (33% above current) after the FDA cleared its Reykjavik manufacturing facility inspection, removing the single biggest regulatory overhang on the stock. The company also reaffirmed full-year guidance on its Q2 call despite a temporary H1 manufacturing slowdown, and management is signaling the most meaningful biosimilar launch cycle since inception. Technically, ALVO is at a 6-month high with the 50-day SMA ($3.72) far below — the stock has broken clean, but it’s now running at the 6mo high with no overhead resistance until the BofA PT at $7. Levels: Exit at $6.00 (Fib 1.272 extension). Support at $4.80 (Fib 23.6% retracement). Note: vol_vs_avg at 0.25 is below average — conviction is modest. Don’t chase past $5.80 without volume confirmation.

EZPW (+8.78%) — $35.05 → $38.46 (+9.7% upside) Thesis: EZCORP is a genuine earnings momentum story — Q3 results showed adjusted EBITDA up 48% YoY to $65.6M with pawn loans hitting a record $382M, driven by jewelry demand and Latin America expansion. This isn’t noise; it’s a consumer stress trade where rising financial pressure drives pawn shop volumes, and the company is executing perfectly while expanding via the SMG deal. Technically, EZPW is pressing against its 6-month high ($35.59) with the 50-day SMA at $31.45 providing a solid floor 10% below. Levels: Exit at $38.46 (Fib 1.272 extension). Support at $33.10 (Fib 23.6%) and $31.56 (Fib 38.2% / near 50d SMA). The RSI of 14 is technically screaming oversold on a weekly basis — this is a momentum continuation setup, not overextended.

MRVL (+6.2%) — $243.50 → $259.54 (+6.6% upside near term) | Bull case $381.83 Thesis: MRVL delivered $2.91 EPS and the headline that matters most — Alphabet is diversifying custom AI chips to Marvell away from Broadcom, a massive competitive win that validates MRVL’s custom silicon strategy. The news that these earnings are “a bigger deal for the AI trade than Nvidia” is a reasonable take: it confirms hyperscaler custom ASIC demand is real and multi-vendor. BofA just put it on an enhanced buying list. Technically, MRVL is between its 50-day SMA ($232) and the Fib 23.6% resistance at $259.54 — there’s room to run before hitting a wall. Levels: Exit near-term at $259.54 (Fib 23.6% resistance from 6mo high pullback); extended target $381.83 (Fib 1.272 extension). Support at $224.39 (Fib 38.2%) and $232 (50-day SMA). This has legs — the Alphabet custom chip win is a secular share gain, not a cyclical bounce.

FCFS (+4.95%) — $236.43 → $251.53 (+6.4% upside) Thesis: FirstCash is a quietly dominant pawn operator (3,300+ stores across US/Latin America) that just beat Q2 revenue estimates with 29.4% YoY growth and $2.50 non-GAAP EPS (4.8% beat) — and is up 61% in the past year with analysts still seeing upside. The bull thesis is straightforward: inflation and consumer financial stress drive pawn demand, the company is expanding internationally, and it’s being carried in quality small-cap funds (Zacks, Heartland Value) with continued upgrades. At a new 6-month high, the technical picture is clean — above all moving averages, momentum intact. Levels: Exit at $251.53 (Fib 1.272 extension). Support at $225.12 (Fib 23.6%) and $217.53 (Fib 38.2%). RSI of 10.94 is a data anomaly here — treat this as momentum continuation at all-time highs, not oversold bounce.

MRNA (+7.05%) — $148.68 → $174.38 (near-term resistance, prior 20d high) Thesis: The cancer vaccine catalyst is the real deal — Merck and Moderna’s mRNA-based cancer vaccine just proved efficacy, and the ripple effects across the mRNA platform are significant. MRNA is also seeing analyst attention (Wall Street top calls today include Moderna), and the stock is up 136% in a week, suggesting multiple catalysts are compounding. However, be honest about the risk: this is a stock coming off multi-year lows ($45 six months ago) that has already run 136% in a week, and the Fib 23.6% support from the 6mo swing sits at $143.93 — barely below current price. Levels: Near-term exit at $174.38 (20d high / 6mo high re-test). Support at $143.93 (Fib 23.6%) — a break below here opens $125. This is a momentum trade only — the 136% weekly gain means the easy money is made. Only for risk-tolerant traders with tight stops.

CDLR (+8.96%) — $26.12 → $31.87 (+22% upside) Thesis: Cadeler completed the He Dreiht 960MW offshore wind installation and simultaneously acquired Menck (specialist offshore foundation equipment) for $578M and signed a $929M contract for two new T-class vessels — this is a company in full acceleration mode in one of the most capital-intensive, high-barrier infrastructure sectors. An analyst pegged CDLR as 23% undervalued post He Dreiht completion. Technically, the stock is right at its 20-day high with the 50-day SMA at $22.74 providing strong floor support. Levels: Exit at $31.87 (Fib 1.272 extension). Support at $26.34 (Fib 38.2%) and $22.74 (50-day SMA). The RSI of 11.52 is suspiciously low for a stock at its 20-day high — treat with caution on data quality, but the fundamental case is solid.

CNK (+4.92%) — $38.40 → $41.92 (+9.2% upside) Thesis: Cinema stocks (AMC, CNK, others) surged Monday with no company-specific headline — this is sector rotation/sympathy buying, the weakest type of catalyst. CNK is at record profitability with rising estimates, and the upgrade cycle is real (recent analyst upgrade flagged it as better positioned than AMC), but the lack of a specific catalyst on the day of the move is a yellow flag. The RSI of 65.4 is the only one in the top 20 in genuinely overbought territory, and at current price CNK is pressing its 6-month high. Levels: Exit at $41.92 (Fib 1.272 extension). Support at $35.34 (Fib 23.6%) and $33.95 (50-day SMA). Trade the sector rotation for now but don’t hold through weakness — no fundamental news = first sign of broad market pressure sends this back to $35.

Headlines to Watch

“Forget Nvidia, These Earnings Are a Bigger Deal for the AI Trade” (MRVL) — Marvell’s Alphabet custom chip win signals hyperscaler ASIC demand is multi-vendor, which is bullish for the entire custom silicon ecosystem (MRVL, AVGO, INTC) and sets the table for NVIDIA Wednesday.
“Cancer Vaccine Breakthrough Lifts 5 Biotech Names” (MRNA + biotech) — Merck/Moderna’s cancer vaccine efficacy data is a landmark mRNA platform validation; watch for secondary beneficiaries in CDMOs and mRNA infrastructure plays beyond just MRNA itself.
“Strive Buys $81.5M in Bitcoin After Issuing More Shares” (ASST) — Bitcoin treasury strategy stocks (ASST, MSTR) are rallying on CEO Matt Cole calling the bear market over; note that BTC per fully diluted share rose only 1.4% on the $81.5M purchase — dilution risk is real for shareholders.
“Dollar at 3-Month Lows on Treasury Buyback Plans” — Dollar weakness is a structural tailwind for gold miners (SA/Seabridge), commodity names (KRO), and emerging market exposure; position in hard assets while this trade has legs.
“Is Broadcom in Trouble Now That Alphabet Is Getting Chips From Marvell Too?” — Alphabet diversifying away from AVGO toward MRVL for custom silicon is a genuine competitive threat to Broadcom’s AI revenue concentration — watch AVGO for a potential negative re-rating.
“NVIDIA Earnings May Come Down to Guidance and Jensen Huang’s Confidence” — Street expects $92B in quarterly revenue; the reaction will hinge entirely on forward guidance language. A beat-and-raise with confident tone could be the catalyst for the next leg in the AI trade. A cautious tone on Blackwell supply chain = broader tech selloff.
“Nearly Two-Thirds of the S&P 500 Already Selling Off in a Big Way” — Beneath the index-level calm, the breadth deterioration is real; this argues for stock-picking over index exposure and watching rotation signals carefully as mega-cap tech carries the weight.

Claude’s Top Picks

MRVL (+6.2% today, +12.7% week) — $243.50 → $259.54 (+6.6% near-term) | $381.83 extended Valuation: No comps provided, but at a $244 price with an analyst target of $266 and a confirmed Alphabet custom chip relationship, the stock is trading at a discount to fundamental value in a sector with multiple expansion tailwinds. Upside: The Alphabet custom ASIC win is a secular share gain from Broadcom — this is not priced in yet, and NVIDIA’s earnings Wednesday will re-energize the entire AI semiconductor sector. Risk: If NVIDIA guides cautiously on Wednesday, the entire AI chip complex sells off regardless of MRVL’s individual merits; support at $224 (Fib 38.2%) would be a painful 8% drawdown.

EZPW (+8.78% today, +19.7% week) — $35.05 → $38.46 (+9.7%) Valuation: No forward P/E comps provided, but 48% EBITDA growth with record pawn loan balances at $382M against a stock still near 6-month highs suggests the earnings multiple hasn’t fully re-rated to reflect the new earnings power. Upside: Consumer financial stress is a durable tailwind — pawn demand doesn’t slow until credit markets ease significantly, and EZCORP’s Latin America expansion adds a growth vector uncorrelated to US macro; CFO presentation at Canaccord conference signals continued investor education/re-rating ahead. Risk: Scrap margin normalization (flagged on the earnings call) could compress Q4 margins, and the SMG integration carries execution risk; any guidance cut would hit this hard given the recent run.

FCFS (+4.95% today, +9.3% week) — $236.43 → $251.53 (+6.4%) Valuation: No forward P/E comps in the data, but a stock up 61% in a year with analysts still calling for upside and 29.4% revenue growth suggests it’s not yet at a euphoric multiple — Heartland Value Fund ownership confirms a value-discipline buy, not a speculative one. Upside: FirstCash and EZCORP are both benefiting from the same macro tailwind (consumer stress → pawn demand), but FCFS is the larger, more diversified operator with 3,300+ stores and UK exposure adding optionality; new 6-month high with clean technicals. Risk: A sudden improvement in consumer credit conditions (rate cuts, strong employment) would be the thesis killer; also, insider sells have been noted in the sector recently — monitor for FCFS-specific selling activity.

ALVO (+18.51% today, +35.3% week) — $5.25 → $6.00 (+14.3%) Valuation: Pre-profitability biosimilar developer — valuation is purely on pipeline/launch cycle; BofA’s $7 PT implies 33% upside from current with the FDA inspection overhang cleared, which is the most important de-risking event a manufacturing-dependent biotech can have. Upside: The biosimilar launch cycle story is real — FDA-cleared facility + reaffirmed guidance + BofA initiation is a trifecta of catalysts that should attract institutional buyers who were sidelined by regulatory risk; the 50-day SMA at $3.72 is far below, so there’s minimal near-term overhead technical resistance. Risk: The volume ratio of 0.25 (below average) means conviction buyers haven’t shown up in force yet — if volume doesn’t confirm the BofA-driven breakout this week, this fades back to $4.50; also a 5-day 35% run means early buyers are sitting on gains and will sell into strength.

CDLR (+8.96% today, +12.0% week) — $26.12 → $31.87 (+22.0%) Valuation: No comps in data, but an analyst explicitly flagged 23% undervaluation post He Dreiht completion, and the combination of a $929M vessel order + $578M Menck acquisition signals management confidence in multi-year offshore wind demand. Upside: Offshore wind installation is a structural secular build-out — CDLR is one of the few companies with specialized vessels for the largest next-generation turbines, and the Menck acquisition adds a vertically integrated competitive moat; 22% upside to Fib 1.272 is achievable over 2 weeks on fundamental re-rating. Risk: The Menck acquisition at $578M is financed with debt (€380M facility) — leverage increases at exactly the time vessel construction costs are rising, and any offshore wind permitting delays (particularly in Europe) could stall the revenue ramp and pressure the balance sheet.

Avoid

ASST (+8.29% today, +49.5% week) — Up 49.5% in a week on Bitcoin treasury strategy and CEO calling the bear market over. The company bought $81.5M in BTC but BTC per fully diluted share rose only 1.4% due to share issuance — this is a dilutive structure masquerading as a Bitcoin bull play. The stock is at its 6-month high ($20.21) with Fib 1.272 extension at $23.55 — already pricing in significant BTC upside. CEO declarations that a bear market is “over” are historically contrarian signals, not entry points. Wait for a pullback to $17.31 (Fib 23.6%) before considering.

MRNA (+7.05% today, +136.1% week) — The cancer vaccine catalyst is legitimate, but a 136% weekly gain from a stock that was at $45 six months ago means the risk/reward has flipped dramatically. The Fib 23.6% support is at $143.93 — only 3% below current price — meaning a relatively small amount of profit-taking would trigger a technical breakdown. Past the 20-day high of $174.38, the next extension isn’t until $209 (Fib 1.272). This is a momentum trade at best; anyone entering today is buying the news that’s already been priced in three times over.

ABCL (+7.94% today, +3.0% week) — AbCellera is up ~64% in the past two weeks on Phase 2 menopausal hot flash data, which is a small, competitive market (neurokinin inhibitors are already approved) and a single-asset biotech bet. The stock is approaching its 6-month high of $12.01 with the nearest Fib extension at $14.41 — only 25% above current price but carrying binary drug development risk. Revenue is down 76.3% YoY and the valuation comps show a negative forward P/E. Clinical biotech bounces on Phase 2 data with no revenue have a poor track record of holding gains into Phase 3 — this is a sell-the-rip setup, not a momentum continuation.

WSB Sentiment Check

NVDA — WSB says: BULLISH (80% bullish, 361 mentions, 3,496 upvotes) Claude says: AGREE — But with a caveat: NVDA is below its 6-month high ($235.47) at $211.51, sitting right on the 50-day SMA ($207.78) with the Fib 50% support at $200.22 not far below. The setup is technically constructive for a pre-earnings squeeze, and MRVL’s blowout gives fundamental cover for bulls. The risk is that $92B revenue is already consensus — Jensen needs to raise guidance meaningfully or the “sell the news” crowd wins. Buy the setup into earnings, but have a plan to exit if he doesn’t blow out the guide.

MU — WSB says: BULLISH (80% bullish, 173 mentions, 2,147 upvotes) Claude says: PARTIALLY AGREE — MU at $943 is below its 6-month high of $1,213 and sitting below the 50-day SMA ($962) and Fib 23.6% support ($1,003) — technically it’s in pullback territory, not breakout mode. The memory cycle thesis (HBM demand for AI) is real, but MU has the most cyclical earnings profile of the AI semi names. WSB is right on the direction but likely early — wait for a reclaim of the 50-day SMA ($962) as confirmation before loading up.

SNDK — WSB says: BULLISH (80% bullish, 94 mentions, 1,780 upvotes) Claude says: DISAGREE — SNDK at $1,547 is in a serious downtrend from its 6-month high of $2,335 (down 34%) and is below its 50-day SMA ($1,637) with the Fib 38.2% support at $1,644 acting as overhead resistance. The stock is between the Fib 38.2% ($1,644) and 50% ($1,431) retracement levels — a textbook dead-cat bounce zone. WSB is bottom-fishing in a broken chart. There’s no fundamental catalyst in the news, and the technical structure remains bearish until a reclaim of $1,644+.

MSTR — WSB says: MIXED (55% bullish, 67 mentions, 161 upvotes) Claude says: AGREE WITH THE MIXED CALL — MSTR at $121 is 38% below its 6-month high of $195.94, below all key Fib levels (Fib 61.8% support at $125.72 is above current price — it’s already through it), and only recently bounced off the $92.52 20-day low. The only bull case is a BTC rip, and BTC signals are mixed at best. The 55% bullish reading is right — this is a coin flip tied entirely to crypto sentiment. Not a high-conviction long here; more of a lottery ticket on BTC momentum.

META — WSB says: BULLISH (80% bullish, 55 mentions, 157 upvotes) Claude says: PARTIALLY AGREE — META at $565.92 is in a clear pullback from the $687.91 6-month high (down 18%) and is below its 50-day SMA ($592.78). The Fib 61.8% support at $587.38 is above current price, meaning META has broken through what should have been support — a technically bearish sign. However, the fundamental story (AI-driven ad monetization, Llama ecosystem, strong FCF) remains one of the best in mega-cap tech. WSB is right on the direction long-term but the chart is warning of more near-term downside; accumulate in tranches toward $540-$550, not all-in at current.

Earnings Scorecard

MRVL — REPORTED | EPS: $2.91 actual | Stock: +6.2% | Recent report The reaction is justified and arguably insufficient — Alphabet diversifying custom AI chips to Marvell is a company-specific secular win that should command a higher multiple re-rating than a single-day 6% move. Buy-the-dip on any weakness toward $232 (50-day SMA).

SMTC — REPORTED | EPS: -$0.41 | Stock: +5.04% Positive reaction to a loss-reporting company suggests the beat was on revenue/guidance, not bottom-line EPS. Given analyst targets at $201 vs. current price (likely much lower given the EPS), this could be a turnaround beat worth monitoring. Hold and watch for analyst upgrade cycle.

BNS — REPORTED | EPS: $5.26 | Stock: +3.29% Record wealth management result drove the beat; Jefferies rated Hold post-print, suggesting the upside is acknowledged but not enough to upgrade. Reaction is fair — hold if you own it, not a new buy.

M (Macy’s) — REPORTED | EPS: $2.42 | Stock: -2.97% Macy’s trading at 10x earnings but still declining — the market is saying the earnings power is structurally declining, not temporarily depressed. The sell-off is justified. Avoid — value trap, not value opportunity.

WSM (Williams-Sonoma) — REPORTED | EPS: $8.92 | Stock: -2.21% Analyst target of $231.80 vs. a stock that likely trades well above that — this is a “good but not good enough” reaction in a high-expectation name. Sell-the-rip if you’re long; not a buy-the-dip candidate at premium multiples.

ADSK — REPORTED | EPS: $6.84 | Stock: -2.17% One analyst flagged ADSK as 32% undervalued following Q2 preview, and the -2.17% reaction suggests guidance or billings disappointed. Analyst target of $314.57 implies meaningful upside if the execution improves. Potential buy-the-dip for patient investors — watch Q3 guidance carefully.

WDAY — REPORTED | EPS: $3.21 | Stock: -1.98% Analyst target of $187.55 vs. likely current price suggests the stock is fairly valued and the reaction is muted. Enterprise software spending patterns are soft broadly. Hold — not a compelling entry.

INTU — REPORTED | EPS: $16.40 | Stock: -1.59% Analyst target of $444.50 implies the stock is at or above fair value at current levels — the mild selloff reflects a “priced to perfection” setup. Sell-the-rip; not a buy.

BBY (Best Buy) — REPORTED | EPS: $5.40 | Stock: -1.82% Analyst target of $83.40 is in line with or below current price, confirming the stock is fairly valued even after the earnings beat. Consumer electronics demand remains soft despite AI upgrade cycle hype. Avoid.

OKTA — REPORTED | EPS: $1.34 | Stock: -0.48% Flat-to-down on what was likely a slight beat suggests the cybersecurity re-rating from the 2024-2025 breach cycle is fully priced. Analyst target of $146.34 may be close to current. Hold — no urgent action either way.

This brief is for informational purposes only and does not constitute investment advice. All technical levels and targets are based on available data as of August 25, 2026. Past performance is not indicative of future results.